Division of Transplantation, Department of Surgery, Vienna General Hospital, Medical University of Vienna, 1090 Vienna, Austria.
Nat Rev Nephrol. 2010 Oct;6(10):594-605. doi: 10.1038/nrneph.2010.110. Epub 2010 Aug 31.
The major factors that limit the success of organ transplantation are the host immune response to the foreign graft and the adverse effects of the chronic immunosuppressive therapy required to suppress this immune response. Deliberately establishing tolerance towards the donor tissue by reprogramming the immune system of the recipient thus holds great promise in improving organ transplant survival and eliminating the untoward effects of chronic drug therapy. The transplantation of donor bone marrow into recipients who are appropriately conditioned to allow development of either full or mixed chimerism has long been recognized to effectively induce donor-specific tolerance. Despite the demonstrated effectiveness of this technique, use of the mixed chimerism strategy in regular clinical practice has been hampered by the toxic side effects inherent to conventional bone marrow transplantation protocols. This Review addresses recent advances in preclinical and clinical studies inducing transplantation tolerance through mixed chimerism and discusses both the potential and the challenges of this approach.
限制器官移植成功的主要因素是宿主对异体移植物的免疫反应,以及抑制这种免疫反应所需的慢性免疫抑制治疗的不良影响。通过重新编程受者的免疫系统,有意使受者对供体组织产生耐受性,从而有望提高器官移植的存活率,并消除慢性药物治疗的不良影响。将供体骨髓移植到经过适当调理以允许完全或混合嵌合体形成的受者体内,长期以来一直被认为能有效地诱导供体特异性耐受。尽管该技术已被证明有效,但由于传统骨髓移植方案固有的毒性副作用,混合嵌合体策略在常规临床实践中的应用受到了阻碍。这篇综述讨论了通过混合嵌合体诱导移植耐受的临床前和临床研究的最新进展,并讨论了该方法的潜在优势和挑战。